Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECC 2015 | Biomarker-directed, multi-drug, phase 1b trial in bladder cancer

Hendrik-Tobias Arkenau • 26 Sep 2015
ECC 2015

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, from Sarah Cannon Research Institute UK, London, UK, discusses an open-label, biomarker-directed, multi-drug, multi-center, multi-arm, randomized phase 1b clinical trial in patients with muscle-invasive urothelial carcinoma of the bladder who have progressed on prior treatment.

More from Hendrik-Tobias Arkenau

ASCO 2016 highlights for immunotherapy
2:15
ASCO 2016 highlights for immunotherapy
Hendrik-Tobias Arkenau • 3 Jun 2016
The BILCAP study: a better overal survivial of biliary tract cancers with adjuvant capecitabine
1:40
The BILCAP study: a better overal survivial of biliary tract cancers with adjuvant capecitabine
Hendrik-Tobias Arkenau • 20 Jun 2017
Reducing the neurotoxic side effects of adjuvant chemotherapy for colon cancer
1:44
Reducing the neurotoxic side effects of adjuvant chemotherapy for colon cancer
Hendrik-Tobias Arkenau • 20 Jun 2017
Combination immunotherapy in gastrointestinal cancers: highlights from ASCO 2017
1:55
Combination immunotherapy in gastrointestinal cancers: highlights from ASCO 2017
Hendrik-Tobias Arkenau • 20 Jun 2017
The content of VJOncology is intended for healthcare professionals